



OPEN ACCESS

Approved by:
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

***Correspondence:**
Rita Falcioni
rita.falcioni@ifo.gov.it
Roberta Maestro
maestro@cro.it

†These authors have contributed
equally to this work and share first
authorship

‡These authors share last authorship

Specialty section:
This article was submitted to
Cancer Molecular Targets and
Therapeutics,
a section of the journal
Frontiers in Oncology

Received: 11 May 2020
Accepted: 13 May 2020
Published: 23 June 2020

Citation:
Racanelli D, Brenca M, Baldazzi D,
Goeman F, Casini B, De Angelis B,
Guercio M, Milano GM, Tamborini E,
Busico A, Dagrada G, Garofalo C,
Caruso C, Brunello A, Pignochino Y,
Berrino E, Grignani G, Scotlandi K,
Parra A, Hattinger CM, Ibrahim T,
Mercatali L, De Vita A, Carriero MV,
Pallocca M, Loria R, Covello R,
Sbaraglia M, Dei Tos AP, Falcioni R
and Maestro R (2020) Corrigendum:
Next-Generation Sequencing
Approaches for the Identification of
Pathognomonic Fusion Transcripts in
Sarcomas: The Experience of the
Italian ACC Sarcoma Working Group.
Front. Oncol. 10:944.
doi: 10.3389/fonc.2020.00944

Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group

Dominga Racanelli^{1†}, Monica Brenca^{1†}, Davide Baldazzi^{1†}, Frauke Goeman^{2†}, Beatrice Casini^{2†}, Biagio De Angelis³, Marika Guercio³, Giuseppe Maria Milano³, Elena Tamborini⁴, Adele Busico⁴, Gianpaolo Dagrada⁴, Cecilia Garofalo⁵, Chiara Caruso⁵, Antonella Brunello⁶, Ymera Pignochino⁷, Enrico Berrino⁸, Giovanni Grignani⁷, Katia Scotlandi⁹, Alessandro Parra⁹, Claudia Maria Hattinger⁹, Toni Ibrahim¹⁰, Laura Mercatali¹⁰, Alessandro De Vita¹⁰, Maria Vincenza Carriero¹¹, Matteo Pallocca², Rossella Loria², Renato Covello², Marta Sbaraglia¹², Angelo Paolo Dei Tos^{12,13}, Rita Falcioni^{2*†} and Roberta Maestro^{1*†}

¹ Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, Aviano, Italy, ² Department of Research, Diagnosis and Innovative Technology, IRCCS Regina Elena National Cancer Institute, Rome, Italy, ³ Department of Onco-Haematology and Cell and Gene Therapy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ⁴ Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ⁵ Advanced Translational Research Laboratory, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, ⁶ Medical Oncology 1, Department of Oncology, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, ⁷ Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy, ⁸ Unit of Pathology, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy, ⁹ Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, ¹⁰ Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ¹¹ Tumor Progression Unit, Department of Experimental Oncology, Istituto Nazionale Tumori Fondazione “G. Pascale” IRCCS, Naples, Italy, ¹² Department of Pathology, Azienda Ospedaliera Universitaria di Padova, Padua, Italy, ¹³ Department of Medicine, University of Padua School of Medicine, Padua, Italy

Keywords: sarcoma, molecular diagnosis, fusion transcripts, NGS, anchored multiplex PCR, hybrid capture-based panel

A Corrigendum on

Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group by Racanelli, D., Brenca, M., Baldazzi, D., Goeman, F., Casini, B., De Angelis, B., et al. (2020). *Front. Oncol.* 10:489. doi: 10.3389/fonc.2020.00489

In the original article, the Ethics Statement was incomplete as it only included the name of one of the institutions. The corrected statement appears below.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethic committee Istituto Ortopedico Rizzoli IRCCS, Regina Elena National Cancer Institute IRCCS, Bambino Gesù Children's Hospital IRCCS and by the proper institutional review boards of the CRO Aviano IRCCS National Cancer Institute, Veneto Institute of Oncology (IOV) IRCCS, University of Padua, Candiolo Cancer Institute FPO-IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Meldola IRCCS, Istituto Nazionale dei Tumori di Milano Fondazione IRCCS. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2020 Racanelli, Brenca, Baldazzi, Goeman, Casini, De Angelis, Guercio, Milano, Tamborini, Busico, Dagrada, Garofalo, Caruso, Brunello, Pignochino, Berrino, Grignani, Scotlandi, Parra, Hattinger, Ibrahim, Mercatali, De Vita, Carriero, Pallocca, Loria, Covello, Sbaraglia, Dei Tos, Falcioni and Maestro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.